Abstract The 2022 World Health Organization (WHO) classification of the urinary and male
genital tumors was recently published by the International Agency for Research on Cancer …

Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Intraductal carcinoma of the prostate (IDC-P) is a lethal prostate cancer subtype that
generally coexists with invasive high-grade prostate acinar adenocarcinoma (PAC) but …

Background Intraductal (IDC) and cribriform (CRIB) histologies in prostate cancer have been
associated with germline BRCA2 (gBRCA2) mutations in small retrospective series, leading …

A key challenge in the management of localized prostate cancer is the identification of men
with a high likelihood of progression to an advanced, incurable stage. Patients who harbour …

Prostate cancer is frequently characterized as a multifocal disease with great intratumoral
heterogeneity as well as a high propensity to metastasize to bone. Consequently, modeling …

Aims Intraductal and cribriform carcinoma of the prostate are increasingly recognised as
independent prognosticators of poor outcome, both in prostate biopsies and surgical …

Intraductal carcinoma of the prostate gland (IDCP), which is now categorised as a distinct
entity by WHO 2016, includes two biologically distinct diseases. IDCP associated with …

Objectives To investigate the genetic alterations of patients with prostate cancer (PCa) with
and without intraductal carcinoma of the prostate (IDC‐P). Patients and Methods We …